ResMed shares rise on strong Q2 result

Let's see how this sleep treatment company performed during the second quarter.

| More on:
A man holding a cup of coffee puts his thumb up and smiles while at laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ResMed Inc (ASX: RMD) shares are rising on Friday morning.

At the time of writing, the sleep disorder treatment company's shares are up 0.5% to $40.70.

This follows the release of the company's second quarter update before the market open.

ResMed shares higher on Q2 update

For the three months ended 31 December, ResMed reported a 10% increase in revenue to US$1.3 billion. This was ahead of the US$1,265 million that Goldman Sachs was forecasting for the three months.

This reflects increased demand for the company's sleep devices and masks portfolio, as well as solid growth across its Residential Care Software business.

Revenue in the Americas, excluding Residential Care Software, grew by 12%. Whereas revenue in Europe, Asia, and other markets, excluding Residential Care Software, grew by 8% in constant currency. Finally, Residential Care Software revenue increased by 8% on a constant currency basis.

ResMed revealed that its gross margin increased by 300 basis points mainly due to manufacturing and logistics efficiencies and component cost improvements. Non-GAAP gross margin increased by 230 basis points due to the same factors.

This ultimately led to ResMed reporting a 52% increase in income from operation to US$417.2 million and a 29% jump in non-GAAP net income to US$358.3 million. The latter was ahead of Goldman's estimate of US$349 million.

Management commentary

ResMed chair and CEO Mick Farrell was pleased with the company's performance during the quarter. He said:

Our second quarter fiscal year 2025 top-line growth, margin expansion, and double-digit EPS growth were the result of increased demand for our sleep health and breathing health products and digital health solutions that people love, as well as our laser-focus on operational excellence.

We delivered 10% year-over-year revenue growth, 230 bps improvement in gross margin, and $309 million of operating cash flow. These results are a continuation of the incredible commitment from our team to create a clear market-leading value proposition in connected digital health.

Farrell also spoke positively about the company's future and believes that ResMed is well-placed for growth. This is being supported by smart watches now being able to diagnose sleep apnoea, which could drive increased awareness. He said:

Our ecosystem is unmatched and ResMed is well-positioned to capitalize on the once-in-a-generation opportunities we have with the recent introduction and adoption of consumer wearables that track sleep health, as well as use of GLP-1 therapies.

We believe these developments will drive increased patient flow as we continue to educate people on the benefits of healthy sleep and breathing, with care delivered right in their own home.

Should you invest $1,000 in Resmed Inc. right now?

Before you buy Resmed Inc. shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Resmed Inc. wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

Investor looking at falling ASX share price on computer screen
Earnings Results

2 ASX All Ords shares crashing 16%+ on earnings updates

It's a red day for the market on Friday.

Read more »

A young man sitting at an outside table uses a card to pay for his online shopping.
Earnings Results

2 ASX 300 consumer stocks making big moves on results day

Let's see how investors have responded to these results on Friday.

Read more »

Woman holding gold bar and cheering.
Earnings Results

Newmont share price sees green as gold prices deliver in FY24

Things continue shining brightly for the gold miner.

Read more »

rising gold share price represented by a green arrow on piles of gold block
Earnings Results

2 ASX 200 gold shares grabbing headlines on record-setting results today

The ASX 200 gold miners delivered record profits and surging dividends.

Read more »

A businessman carrying a briefcase looks at a square peg or block sinking into a round hole.
Earnings Results

Block share price tanks 8% on FY24 results

Investors didn't wait to react to the company's 2024 numbers.

Read more »

Delighted adult man, working on a company slogan, on his laptop.
Earnings Results

QBE share price lifts off on 31% final dividend boost

ASX 200 investors are piling into QBE shares on Friday. Is this why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Earnings Results

Guzman Y Gomez share price sinks 8% on half year results

A poor performance in the US appears to be overshadowing strong growth in Australia.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Earnings Results

Telix share price jumps 13% on FY24 profit surge

This pharma stock has delivered another stunning result. Here's what it reported.

Read more »